Condition: Rheumatoid Arthritis · Sponsor: Sonoma Biotherapeutics, Inc.
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown. Following completion of the initial single ascending dose cohorts, the study may evaluate alternative administration regimens of SBT777101, including split-dose administration. In the split-dose cohort, participants may receive two intravenous infusions of SBT777101 derived from a single manufacturing process, administered approximately 6 weeks apart. The study will continue to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity.
This description comes directly from the study's public registry record.
Sabrina Fox-Bosetti, MPH · 415-992-6245 · clinicaloperations@sonomabio.com
Jason Do · 415-992-6245 · clinicaloperations@sonomabio.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Scottsdale, Arizona, United States | Recruiting |
| UCSF Medical Center | San Francisco, California, United States | Recruiting |
| Stanford Medical Center | Stanford, California, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Tufts University | Boston, Massachusetts, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Oregon Health Sciences University | Portland, Oregon, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06201416